Ayush Ministry Clarifies No Further Retention Or Renewal Fees After One Time Registration Of ASU Products

New Delhi : Following its move to amend rules on manufacturing of Ayurveda, Siddha and Unani (ASU) drugs through a notification in October this year, the Ministry of Ayush has clarified to the State Licensing Authorities (SLAs) that there will be no further retention or renewal fees after the one time registration of products, as specified in the notification.

In a clarification to the SLAs this month, the Ministry communicated that the manufacturing units of the ASU drugs will be subjected to inspection in a randomised manner every five year while previously this duration of inspection was twice a year. The amendments, under the Drugs (4th Amendment) Rules, 2021, notified on October 1, are aimed to reduce the compliance burden and facilitate ease of doing business.

Through the notification, the Ministry has fixed a one time registration fee as Rs. 2,000 for any number of classical or generic ASU drugs and Rs. 3,000 for the first ten proprietary products and after the said ten products, an additional fee of Rs. 2,000 per product. For existing license holders this fee for one time registration is Rs. 1,000 for any number of classical/generic ASU drugs and Rs. 1,000 for the first ten proprietary products and after that, an additional fee of Rs. 1,000 per product.

“It is to be noted that there will be no further retention or renewal fees thereafter,” said the letter from the Ministry to the SLAs.

“The license of the ASU drugs have been made perpetual i.e. with one time registration fee the license of the product will be valid lifetime subject to online submission of self compliance declaration every year or unless suspended or cancelled. While prior to the notification, it had a validity period of five years,” it said.

The mode of online payment is not at present integrated on the e-aushadhi portal and all submission of fees is through the existing challan system and the receipt of the same is uploaded on the portal for further processing of the application.

“Under Form 25D and 25E it is mandatory for the licensing authority to mention the names of drugs categorised as per Schedule T (each item to be separately specified) with specific Product Code/QR Code for each approved drug,” it added. The fees over and above the first 10 products of patent and proprietary category under the relevant rules will be accordingly calculated for approvals on or after October 1, 2021, said the clarification.

The Ministry has made the process of grant license to manufacture ASU drugs swift, paperless and more transparent by making the license application system online. However, for six months from the date of gazette notification, both online and offline application process will co-exist before it turns completely online.

The amendment also inserted a form for Application for the Certificate of Good Manufacturing Practices (GMP) for Ayurvedic, Siddha or Unani drugs manufacturing units with fees of Rs. 5,000. The applicants will only have to get their GMP certification validated every five years to keep their license in force. The GMP certificate can also be retained with submission of retention fee of Rs. 1,000 every year.

The maximum time in granting the license to manufacture ASU drugs has been reduced from three months to two months, through the amendment.

Issuance of free sale certificate has been made online and non conviction certificate also moved online with submission of notarised affidavit. The validity of non conviction certificates has been increased from six months to one year.

The notification has no retrospective effect and is applicable prospectively. Those who have applied for the licence before October 1, 2021, along with the old fees structure may be considered according to the rates/retirements prevalent on the date of applications. In such cases while issuing a license the date of application may also be mentioned prominently.

  • Related Posts

    • Pharma
    • July 24, 2025
    • 180 views
    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

    • Pharma
    • July 22, 2025
    • 270 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra